Plus   Neg

Prothena Corp. (PRTA) Is Up On Phase 1 Study Results

Prothena Corp. (PRTA) announced after the bell Tuesday that results from its Phase 1b study of PRX002/RG7935 were published in JAMA Neurology. PRX002/RG7935 was shown to have an acceptable safety and tolerability profile in patients with Parkinson's disease.

Prothena climbed above Tuesday's range in the final hour of trade and closed up by 0.42 at $14.98. The stock is now up 2.99 on 11K shares after the bell.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT